---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-033054"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:42:26.601846+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acurx reports Q4/FY2022 net loss; Phase 2b CDI trial interim IDMC review at 36 patients

## Summary
- Cash $9.1M at Dec 31, 2022 vs $13.0M a year earlier.
- Q4 net loss $3.3M ($0.28/share) vs $2.6M ($0.26); FY net loss $12.1M ($1.12) vs $12.7M ($1.49).
- R&D expense FY2022 $4.8M (up from $2.0M) due to Phase 2b costs; G&A $7.3M (down from $10.8M).
- Phase 2b CDI trial has enrolled 25 of 36 patients needed for IDMC interim review; IDMC may recommend early termination or continue enrollment.
- Non-dilutive grant application for $11.3M for ACX-375 (MRSA) in final round; decision expected in April 2023.

## SEC filing metadata
- accession: 0001104659-23-033054
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/0001104659-23-033054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465923033054/tm239317-2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-033054
- JSON: https://secwatch.observer/filing/0001104659-23-033054.json
- Plain text: https://secwatch.observer/filing/0001104659-23-033054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.